Genomic Predictors of Clinical Outcomes and Benefit of (Chemo)Hormonal Therapy in Metastatic Hormone Sensitive Prostate Cancer

Abstract

Despite rapid changes in the therapy landscape of metastatic prostate cancer which has resulted in improved patient survival, there remains a dearth of predictive biomarkers to guide precision patient care. Our knowledge of the genomic drivers that underpin lethal prostate cancer has grown exponentially. Preclinical and clinical data revea lthat tumor suppressor gene (TSG) aberrations drive rapid castration resistance and poorer patient survival. There is a critical unmet need to discover, train and validate genomic biomarkers in metastatic prostate cancer treated with hormonal therapy alone or in combination with docetaxel chemotherapy.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Mar 01, 2021
Accession Number
AD1125018

Entities

People

  • Anis A Hamid

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Biological Markers
  • Biomedical Research
  • Data Science
  • Deoxyribonucleic Acids
  • Department Of Defense
  • Electronic Mail
  • Gene Expression
  • Genetics
  • Health Services
  • Machine Learning
  • Medical Personnel
  • Neoplasms
  • New England
  • Oncology
  • Prostate Cancer
  • Ribonucleic Acids
  • Statistical Analysis
  • Therapy
  • Urban Areas

Fields of Study

  • Medicine

Readers

  • Molecular and genetic basis of cancer.
  • Oncology
  • Oncology (Cancer Research).